AdJane Biosciences is a clinical-stage, next-generation vaccine platform company that focuses on enabling the development of scalable multivalent vaccines that induce both systemic and mucosal immunity.
Vaccines have transformed public health, building strong systemic immunity across much of the global population and protecting effectively against many severe infectious diseases. Despite this success, a fundamental mismatch persists between the intramuscular administration route of most vaccines and the mucosal surfaces where many pathogens establish infection.
Systemic immunity acts once a pathogen has already entered the body, limiting its spread and preventing severe illness. What it does not provide is immunity at the body’s primary entry points, so pathogens can still take hold there and spread easily to others. Because of this mucosal immunity gap, vaccines are limited in their ability to stop initial infection and reduce transmission.
Our mission is to close this mucosal immunity gap.
Our Nm-nOMV Platform is designed for the development of scalable multivalent vaccines that induce both systemic and mucosal immunity. The platform has been clinically validated in a Phase 1 clinical trial, in which safety, tolerability, and mucosal immunogenicity were demonstrated. Following this success, AdJane is developing its platform further, by means of multiple programs across viral and bacterial indications, demonstrating its breadth. AdJane offers its technology to partners seeking to present their own antigens on a mucosally delivered platform with built-in adjuvanticity.
Interested? Learn more About us. For partnership inquiries, please visit our Contact page.